Coagulopathy Management - Comprehensive Guide with Evidence

1. Definition and Classification

2. Pathophysiology of Trauma-Induced Coagulopathy (TIC)

• Characterized by systemic hyperfibrinolysis, low fibrinogen, and platelet dysfunction
• Driven by tissue hypoperfusion, activated Protein C pathway, and endothelial release of tPA
• Present in up to 25-35% of major trauma patients on arrival

• Hypothermia - impairs enzymatic activity of coagulation cascade
• Acidosis - reduces thrombin generation
• Hypocalcemia - calcium is required for vitamin K-dependent factors (II, VII, IX, X)

Bailey & Love's, p. 1046: "ATC is characterised by systemic hyperfibrinolysis, low fibrinogen levels and platelet dysfunction. ATC evolves into a more complex, multifactorial 'trauma-induced coagulopathy' owing to further derangements induced by resuscitation."

3. Assessment of Coagulopathy

Conventional Lab Tests

• PT/INR - extrinsic pathway (factors VII, X, V, II, fibrinogen)
• aPTT - intrinsic pathway (VIII, IX, XI, XII)
• Platelet count - thrombocytopenia <100,000/mm³ is coagulopathic
• Fibrinogen (Clauss assay) - first factor to fall critically low in hemorrhage
• D-dimer / FDPs - markers of fibrinolysis (elevated in DIC)

Viscoelastic Tests (VET) - Point-of-Care (POC)

Current Surgical Therapy 14e: Use of these point-of-care tests may reduce transfusion requirements. VET-guided therapy allows targeted treatment rather than empirical transfusion.

4. Damage Control Resuscitation (DCR) - Core Framework

Contemporary approach to traumatic injury management (Duque P, et al. Anesth Analg 2020)

4.1 Permissive Hypotension

• Target MAP ~50 mmHg, SBP 80-100 mmHg in hemorrhagic shock
• Rationale: higher pressures disrupt early hemostatic plugs and worsen rebleeding
• Exception: TBI patients require MAP ≥80 mmHg to maintain cerebral perfusion pressure
• Avoid crystalloids and colloids - both worsen dilutional coagulopathy

Current Surgical Therapy 14e, p. 1651: "Patients whose MAP was maintained above 50 mmHg required less IV fluids, fewer blood products, and had lower mortality than patients with a MAP target of 65 mmHg."

4.2 Preventing Hypothermia

• Passive: warm blankets, warm ambient temperature, remove wet/cold clothing
• Active: forced-air warming devices, warmed IV fluids and blood products

4.3 Correcting Acidosis

• Bicarbonate and THAM do not significantly improve hemostasis
• Best treated with hemorrhage control and blood products
• THAM preferred over bicarbonate when reversal of severe acidosis is needed (avoids excess sodium and CO2)

4.4 Correcting Hypocalcemia

• Ionized calcium should be monitored during massive transfusion
• Calcium must be supplemented early - preferably with the first unit of blood (not after several units)
• Citrated blood products combined with hepatic hypoperfusion rapidly cause hypocalcemia
• 2019 European Trauma Guideline recommends regular ionized calcium monitoring and supplementation

5. Blood Product Management

5.1 Massive Transfusion Protocol (MTP)

• Activated early in severe hemorrhage
• Delivers blood components in a 1:1:1 ratio (pRBC : Plasma : Platelets)
• Military experience from Iraq War confirmed 1:1:1 is associated with improved outcomes
• Reduces total blood product use, organ failure, and mortality compared to delayed/unguided transfusion

Bailey & Love's: "Prevention of dilutional coagulopathy is central to the damage control resuscitation of patients who are actively bleeding... delivering balanced transfusion regimes that approximate whole blood. In most practice this means delivering matched units of red blood cells, plasma and platelets in a 1:1:1 ratio."

5.2 Individual Components

• Volume ~250 mL, hematocrit ~70%
• Raises Hb by ~1 g/dL per unit
• RBCs also actively participate in thrombin generation via phosphatidylserine expression
• RBC "margination" shifts platelets to vessel periphery, enhancing adhesion
• Shelf life 42 days (cryopreserved: 10 years)
• Group O pRBC and AB plasma used as universal donors

• Contains all coagulation factors including fibrinogen (~500 mg per 250 mL unit)
• Must be ABO compatible; Rh compatibility not required
• Thaw time ~30 min (rapid thawers: ~2 min for 2 units)
• Once thawed, use within 24 hours (or refrigerate for up to 5 days)
• Lyophilized/freeze-dried plasma (Lyoplas N-w): room-temperature storage for 2 years, reconstituted in minutes - promising for trauma/prehospital use

• Given for thrombocytopenia or observed platelet dysfunction
• Target platelet count >50,000/mm³ in active bleeding; >100,000/mm³ in TBI
• Spontaneous hemorrhage risk when count <20,000/mm³

• Contains high concentrations of fibrinogen, factor VIII, vWF, factor XIII
• Given empirically or guided by VET/lab tests
• First-line fibrinogen replacement in many centers

• Standardized fibrinogen content (advantage over cryoprecipitate)
• Fibrinogen is the first coagulation factor depleted in major hemorrhage
• Values below 229 mg/dL independently associated with significantly increased mortality
• A 2025 meta-analysis (PMID: 39715048) confirmed efficacy of coagulation factor concentrates (including fibrinogen concentrate) in trauma-induced coagulopathy

• 500 mL unit: Hct 38-50%, platelets 15-40×10⁵/µL, 100% clotting factor activity
• Cold-stored low-titer group O whole blood (LTOWB) used in civilian settings
• ~50% reduction in post-ED blood product use vs component therapy
• Questions remain on leukoreduction and large-volume transfusion

6. Tranexamic Acid (TXA) - Key Evidence

• 1 g IV loading dose within 3 hours of injury, followed by 1 g over 8 hours (CRASH-2 protocol)
• Administration after 3 hours is NOT recommended (may increase mortality)
• Prehospital (Committee on Tactical Combat Casualty Care): single 2 g dose
• ACS-COT/ACEP guidelines: give when HR >120 bpm and/or SBP <90 mmHg

• Largest RCT on TXA in trauma
• TXA given within 3 hours reduced all-cause mortality by 9% (RR 0.91)
• Mortality from hemorrhage reduced by 15%
• Administration after 3 hours was associated with increased mortality
• Tintinalli's EM: "Based on the CRASH-2 trial, the risk of death was most reduced with tranexamic acid administration within 1 hour of injury"

7. DIC Management

• Generally reserved for DIC manifested by thrombosis, acrocyanosis, or in cancer/vascular malformations where active bleeding is absent
• A meta-analysis confirmed: anticoagulant therapy in sepsis-DIC reduces mortality in DIC patients, though with increased bleeding risk
• Use unfractionated heparin by continuous infusion (short half-life, reversible); monitor by clinical response rather than aPTT (unreliable in DIC)

• TXA and aminocaproic acid are generally contraindicated in DIC - block secondary fibrinolysis and can precipitate thrombosis
• Exception: life-threatening hemorrhage refractory to blood components - use with simultaneous low-dose heparin

• Improve laboratory parameters but neither reduces mortality significantly

• Covers trauma, burn, obstetric, pancreatitis, and liver failure-associated DIC
• Recommends individualized management based on the dominant phenotype (bleeding vs thrombotic)

8. Anticoagulant Reversal

Harrison's (2025): "Four-factor prothrombin complex concentrate (25-50 units/kg) is effective at restoring hemostasis. If there is continued bleeding, activated PCC (50 units/kg) or recombinant factor VIIa (90 µg/kg) can be considered."

9. Liver Disease Coagulopathy

• Synthetic failure of factors II, V, VII, IX, X, fibrinogen, Protein C/S
• Additionally: thrombocytopenia from portal hypertension / hypersplenism
• Management:
  • FFP for acute bleeding (not prophylactically)
  • Platelet transfusion for thrombocytopenia with active bleeding
  • Cryoprecipitate for low fibrinogen (<100 mg/dL)
  • Vitamin K 10 mg IV for suspected vitamin K deficiency
  • Avoid routine correction of INR without active bleeding (INR does not predict bleeding in cirrhosis - balanced coagulopathy)

10. Intraoperative Coagulopathy (Liver Transplantation)

Mulholland & Greenfield's Surgery 7e: Complex coagulopathy arises from synthetic deficiency + portal hypertension + thrombocytopenia. Worsened during anhepatic phase and post-reperfusion (release of tPA from graft causing fibrinolysis). Monitor with conventional tests AND VET (TEG/ROTEM). Maintain normal pH, calcium, and normothermia to support coagulation. Fibrinolysis after reperfusion typically resolves once graft function is restored.

11. Obstetric Coagulopathy / PPH

• Transfusion practices adapted from trauma data
• Hypothermia, acidosis, and coagulopathy occur in both traumatic and obstetric hemorrhage
• ROTEM-guided transfusion reduces unnecessary blood products
• PPH seems to require trauma-level transfusion strategy, particularly regarding fibrinogen levels (Henry's Clinical Diagnosis, Laboratory Methods)
• Postpartum hemorrhage + placenta accreta spectrum: conservative management associated with consumptive coagulopathy - 2024 systematic review (PMID: 38030960) confirms close monitoring and early fibrinogen replacement essential

12. Key Evidence Summary

13. Practical Algorithm Summary

• "Scoop and run", tourniquets, hemostatic dressings, treat hypothermia, minimize fluids

• Permissive hypotension (SBP 80-100 mmHg, MAP >50 mmHg)
• Labs: CBC, PT, aPTT, fibrinogen, ionized calcium, TEG/ROTEM
• Activate MTP early
• TXA 1 g IV within 3 hours of injury
• Calcium administration with first blood unit

• 1:1:1 pRBC:plasma:platelets
• Fibrinogen concentrate / cryoprecipitate for low fibrinogen
• Surgical hemorrhage control, abdominal packing if needed

• Correct hypothermia, acidosis, and residual coagulopathy
• VET-guided targeted transfusion
• Correct calcium, ionized Mg

• Remove packing, definitive repair once coagulopathy resolved and physiology restored